CA3197104A1 - Antagonistes bifonctionnels de l'activine/tgf-beta et rankl et leurs utilisations - Google Patents

Antagonistes bifonctionnels de l'activine/tgf-beta et rankl et leurs utilisations

Info

Publication number
CA3197104A1
CA3197104A1 CA3197104A CA3197104A CA3197104A1 CA 3197104 A1 CA3197104 A1 CA 3197104A1 CA 3197104 A CA3197104 A CA 3197104A CA 3197104 A CA3197104 A CA 3197104A CA 3197104 A1 CA3197104 A1 CA 3197104A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
antibody
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3197104A
Other languages
English (en)
Inventor
Hq Han
Xiaolan Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3197104A1 publication Critical patent/CA3197104A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente divulgation concerne de nouvelles molécules bifonctionnelles comprenant au moins une molécule de liaison RANKL et au moins une molécule de liaison activine ou TGF-?, qui permettent une séquestration de RANKL et de l'activine ou de TGF-? en parallèle. L'invention concerne également des compositions pharmaceutiques de ces molécules antagonistes bifonctionnelles et leurs utilisations thérapeutiques pour traiter divers troubles osseux dont la pathogenèse implique l'activation à la fois des voies de signalisation RANKL-NFKB et activine/TGF-?-Smad2/3, tels que la métastase osseuse, la perte osseuse due au cancer, la fragilité osseuse associée aux maladies neuromusculaires, l'ostéogenèse imparfaite, la fracture, l'ostéopénie et l'ostéoporose.
CA3197104A 2020-11-11 2021-11-05 Antagonistes bifonctionnels de l'activine/tgf-beta et rankl et leurs utilisations Pending CA3197104A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063112380P 2020-11-11 2020-11-11
US63/112,380 2020-11-11
US202063113922P 2020-11-15 2020-11-15
US63/113,922 2020-11-15
PCT/US2021/058181 WO2022103660A1 (fr) 2020-11-11 2021-11-05 Antagonistes bifonctionnels de l'activine/tgf-bêta et rankl et leurs utilisations

Publications (1)

Publication Number Publication Date
CA3197104A1 true CA3197104A1 (fr) 2022-05-19

Family

ID=81601668

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3197104A Pending CA3197104A1 (fr) 2020-11-11 2021-11-05 Antagonistes bifonctionnels de l'activine/tgf-beta et rankl et leurs utilisations

Country Status (7)

Country Link
EP (1) EP4243931A4 (fr)
JP (1) JP2023548346A (fr)
KR (1) KR20230118573A (fr)
AU (1) AU2021377176A1 (fr)
CA (1) CA3197104A1 (fr)
MX (1) MX2023005565A (fr)
WO (1) WO2022103660A1 (fr)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010085996A (ko) * 1999-09-03 2001-09-07 스티븐 엠. 오드레 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
CA2597098C (fr) * 2005-02-08 2016-08-02 Steven R. Ledbetter Anticorps anti-tgf-beta
CL2007002567A1 (es) * 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
CN101952312A (zh) * 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
KR20110044991A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＮＦ-α 길항제 다-표적 결합 단백질
EP2401296A1 (fr) * 2009-02-24 2012-01-04 Glaxo Group Limited Constructions multivalentes et/ou multispécifiques de liaison au rankl
TWI544077B (zh) * 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
EP3202459B1 (fr) * 2009-09-09 2021-04-14 Acceleron Pharma Inc. Antagonistes d'actriib et dosage et utilisations de ceux-ci pour traiter l'obésité ou le diabète en régulant le taux de graisse corporelle
US8993524B2 (en) * 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2013147899A1 (fr) * 2012-03-31 2013-10-03 R-PHARM, CJSC (Closed Joint Stock Company) Composition dérivée de l'ostéoprotégérine et son utilisation
TW201838651A (zh) * 2012-11-01 2018-11-01 美商艾伯維有限公司 穩定雙重可變區域免疫球蛋白蛋白質調配物
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3587448B1 (fr) * 2013-03-15 2021-05-19 Xencor, Inc. Protéines hétérodimériques
TWI655207B (zh) * 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
US10227411B2 (en) * 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CA2980757A1 (fr) * 2015-03-26 2016-09-29 Acceleron Pharma Inc. Proteines de fusion associees a la follistatine et leurs utilisations
US20180008672A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2018026742A1 (fr) * 2016-08-01 2018-02-08 Askgene Pharma Inc. Nouveaux conjugués anticorps-albumine-médicament (aadc) et leurs procédés d'utilisation
PL3615066T3 (pl) * 2017-04-28 2024-04-29 Amgen Inc. Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania
WO2019079762A1 (fr) * 2017-10-20 2019-04-25 Children's National Medical Center Procédés de découverte d'anticorps à l'aide de transcriptomes et compositions dérivées de ceux-ci
JP2022514215A (ja) * 2018-12-05 2022-02-10 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Ｒａｎｋアンタゴニストおよびその使用

Also Published As

Publication number Publication date
WO2022103660A1 (fr) 2022-05-19
AU2021377176A1 (en) 2023-06-22
KR20230118573A (ko) 2023-08-11
EP4243931A4 (fr) 2025-01-01
MX2023005565A (es) 2024-02-23
EP4243931A1 (fr) 2023-09-20
JP2023548346A (ja) 2023-11-16

Similar Documents

Publication Publication Date Title
JP7850417B2 (ja) 新規インターロイキン－２バリアントおよびその二官能性融合分子
JP2024122980A (ja) インターロイキン－２バリアントおよびその使用方法
KR102259085B1 (ko) Edb 표적화 il-12 조성물
CN110505883A (zh) 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
CN120018857A (zh) Gprc5d tcb与imid的组合疗法
US20240343788A1 (en) Novel bifunctional multispecific antagonists capable of inhibiting multiple ligands of tgf-beta family and uses thereof
US20230391863A1 (en) Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
WO2021078123A1 (fr) PROTÉINE RECOMBINANTE CIBLANT PD-1 ET TGFβ
CN118201953A (zh) 新型干扰素变体及其双功能融合分子
US20230391880A1 (en) Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
RU2858732C2 (ru) Бифункциональные антагонисты активина/TGF-бета и RANKL и их применение
AU2021377176A1 (en) Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
RU2851121C1 (ru) Новые бифункциональные мультиспецифические антагонисты, способные ингибировать множественные лиганды семейства tgf-бета, и их применения
US20230391892A1 (en) Bifunctional antagonists of tumor necrosis factor alpha and transforming growth factor beta and uses thereof
CN116917330A (zh) 激活蛋白/TGF-β和RANKL的双功能拮抗剂及其用途
CN116801895A (zh) 新颖的能够抑制TGF-β家族多于一种配体的双功能多特异性拮抗剂及其用途
CN116635059A (zh) 激活蛋白和肿瘤坏死因子-α的双功能拮抗剂及其用途
CN118103406A (zh) 可激活多肽复合物
JP2023510211A (ja) 抗ＮＫｐ３０抗体及び使用方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241021

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241021

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241021

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251014

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251014

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251029

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251029